<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7248559\results\search\disease\results.xml">
  <result pre="the RVFV structural glycoprotein (GP) genes under control of the" exact="vaccinia virus" post="P7.5K early/late promoter inserted into the LSDV viral thymidine"/>
  <result pre="Control animal D2-2's temperature peaked at 42.2°C and it developed" exact="diarrhea" post="6 dpc. One control animal (D2-5) died at 5"/>
  <result pre="as has been the case for other poxviruses such as" exact="vaccinia virus" post="and canarypox virus, but with the added advantage of"/>
  <result pre="of the order Bunyavirales. Arch Virol. (2019) 164:1949–65. 10.1007/s00705-019-04253-631065850 7.DaubneyRHudsonJREnzootic" exact="hepatitis" post="or rift valley fever. J Path and Bact. (1931)"/>
  <result pre="order Bunyavirales. Arch Virol. (2019) 164:1949–65. 10.1007/s00705-019-04253-631065850 7.DaubneyRHudsonJREnzootic hepatitis or" exact="rift valley fever." post="J Path and Bact. (1931) 34:54510.1002/path.1700340418 8.DaviesFG. Risk of"/>
  <result pre="Transient marker stabilisation: a general procedure to construct marker-free recombinant" exact="vaccinia virus." post="Arch Virol. (1998) 143:467–74. 10.1007/s0070500503039572548 19.MollaWde JongCMGariGFrankenaKEconomic impact of"/>
 </snippets>
</snippetsTree>
